Onfi

How Hard Is It to Find Onfi in Stock?

Onfi (clobazam) has faced intermittent supply challenges since around 2020. As of 2026, availability continues to be inconsistent across regions, pharmacy types, and formulations. Generic clobazam tablets are the most reliably available formulation, while the oral suspension (2.5 mg/mL) has been disproportionately affected by supply disruptions and may be unavailable at many pharmacies for extended periods.

The supply challenges are driven by several structural factors: a small specialty patient population (LGS is a rare condition), limited generic manufacturers, DEA Schedule IV production quotas, and the manufacturing complexity of the oral suspension. Independent and specialty pharmacies tend to have more consistent clobazam inventory than large chain pharmacies.

If you're having trouble finding Onfi at your usual pharmacy, medfinder can help. medfinder is a service that calls pharmacies near you to find out which ones have your medication in stock — so you don't have to spend hours on hold. Results are texted directly to you.

Who Can Prescribe Onfi?

Onfi (clobazam) is a Schedule IV controlled substance, so prescribing is governed by both DEA regulations and state controlled substance laws. Any DEA-licensed practitioner may prescribe clobazam, but in practice it is most commonly initiated by specialists with experience in epilepsy management, particularly for complex conditions like LGS.

Typical prescribers include:

• Epileptologists — neurologists with epilepsy subspecialty training; the most experienced in LGS management
• Pediatric neurologists — LGS typically begins in childhood; pediatric neurologists at children's hospitals and neurodevelopmental centers are primary prescribers for pediatric patients
• General neurologists — commonly prescribe clobazam for adult LGS patients with established diagnoses
• Primary care physicians (PCPs) — may continue established clobazam prescriptions initiated by a neurologist
• Nurse practitioners (NPs) and physician assistants (PAs) — may prescribe under collaborative practice agreements with supervising neurologists, depending on state law

Telehealth is available for some clobazam patients. Several telehealth neurology platforms have epileptologists licensed in multiple states who can manage LGS treatment remotely. This is particularly beneficial for patients in rural areas or those with mobility limitations. For new patients requiring an LGS diagnosis or initiation of clobazam, an in-person evaluation is typically required first.

Is Onfi a Controlled Substance?

Yes. Onfi (clobazam) is a Schedule IV (C-IV) controlled substance under the Controlled Substances Act. This means the DEA has determined it has a currently accepted medical use but also has a potential for abuse and dependence, though lower than Schedule I-III drugs.

Schedule IV status has several practical implications for patients: prescriptions for clobazam may be limited to a 30-day supply in some states, early refills may be restricted by pharmacy and state law, the prescription cannot be transferred between pharmacies in most states, and DEA production quotas limit how much clobazam manufacturers are allowed to produce each year. These regulatory constraints contribute to the supply availability challenges patients experience.

Patients taking clobazam should be aware that physical dependence can develop with prolonged use, and abrupt discontinuation carries significant risks including withdrawal seizures and status epilepticus. Onfi should never be stopped suddenly — always taper gradually under the guidance of your prescribing neurologist.

Common Side Effects of Onfi

The most commonly reported side effects of Onfi (occurring in at least 10% more patients than placebo in clinical trials):

• Somnolence or sedation (most common; often improves after the first 4–8 weeks)
• Drooling (hypersalivation)
• Constipation
• Pyrexia (fever)
• Lethargy and fatigue
• Cough and upper respiratory symptoms
• Slurred speech and coordination problems
• Behavioral changes (irritability, aggression — especially in children)

Serious Side Effects (Seek Immediate Medical Attention)

• Respiratory depression: Especially when combined with opioids or alcohol — can be fatal
• Stevens-Johnson Syndrome (SJS) / Toxic Epidermal Necrolysis (TEN): Life-threatening skin reactions; stop medication at first sign of rash
• DRESS: Drug Reaction with Eosinophilia and Systemic Symptoms — rare but life-threatening; FDA warning added December 2023
• Suicidal ideation: ~1 in 500 patients; call your doctor immediately if you experience mood changes or thoughts of self-harm
• Withdrawal seizures / status epilepticus: Can occur with abrupt discontinuation — never stop Onfi suddenly

Final Thoughts on Onfi

Onfi (clobazam) is an important and effective treatment for seizures associated with Lennox-Gastaut syndrome. Its unique 1,5-benzodiazepine structure gives it a favorable anticonvulsant-to-sedation profile compared to other benzodiazepines, and it is well-established in both pediatric and adult LGS management. Generic clobazam, available since 2018, has made the drug significantly more affordable for most patients.

The primary challenge for Onfi patients in 2026 is availability. Intermittent supply disruptions — particularly for the oral suspension — continue to affect access. Proactive planning is essential: establish a relationship with an independent or specialty pharmacy, refill early, know your backup options, and have a contingency plan agreed upon with your neurologist.

When you're struggling to find Onfi in stock, medfinder is here to help. medfinder calls pharmacies near you to find which ones have your medication in stock, so you can spend less time on hold and more time focused on what matters most — seizure control and quality of life.